A5065671989- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Research and Treatments
- Gastric Cancer Management and Outcomes
- Renal cell carcinoma treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Click Chemistry and Applications
- Advanced Breast Cancer Therapies
- Esophageal Cancer Research and Treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer therapeutics and mechanisms
- Heat shock proteins research
- Inflammatory mediators and NSAID effects
- Cancer, Hypoxia, and Metabolism
- Redox biology and oxidative stress
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
Banner MD Anderson Cancer Center
2015-2024
The University of Texas MD Anderson Cancer Center
2015-2024
Banner Health
2012-2020
Brigham and Women's Hospital
2017
Dana-Farber Brigham Cancer Center
2017
Smilow Cancer Hospital
2017
Yale Cancer Center
2017
University of Arizona
2004-2014
Threshold Pharmaceuticals (United States)
2006-2014
University of Arizona Cancer Center
2007-2014
A phase II trial of the oral epidermal growth factor receptor (EGFR) inhibitor erlotinib in patients with gastroesophageal adenocarcinomas stratified according to primary tumor location into two groups: junction (GEJ)/cardia and distal gastric adenocarcinomas.Patients a histologically proven diagnosis adenocarcinoma GEJ or stomach (ST) that was unresectable metastatic; presence measurable disease; no prior chemotherapy for advanced metastatic cancer; Zubrod performance status (PS) 0 1;...
PURPOSE Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab patients microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment fluoropyrimidine, oxaliplatin, irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose the first-line therapy cohort from phase II 142 study. PATIENTS AND METHODS Patients no prior setting for...
TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus patients with previously untreated, locally advanced or metastatic pancreatic cancer.
Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial postoperative adjuvant radiochemotherapy for high risk and adenocarcinoma: Demonstrated superior survival patients who received chemoradiotherapy with bolus fluorouracil (FU) leucovorin (LV) compared surgery alone. CALGB 80101 (Alliance; Phase Adjuvant Chemoradiation Resection Gastric Gastroesophageal Adenocarcinoma) assessed whether a regimen that replaced FU plus...
Abstract Purpose: The purpose of the study was to evaluate stability phosphoprotein as a marker signaling activity in human tumors using clinical samples and xenografts. Experimental Design: expression phospho-Ser473-Akt (p-Akt) assessed by immunohistochemistry paraffin-embedded from patients enrolled Southwest Oncology Group trial gastroesophageal junction Western blotting colon tumor xenografts at various times after removal animal. Results: Clinical had evaluable p-Akt staining only when...
4003 Background: Following curative resection of gastric or GEJ adenocarcinoma, INT-0116 demonstrated superior survival for pts who received postoperative bolus 5-FU and leucovorin (LV) before after concomitant RT compared to surgery alone. We assessed whether a chemoRT regimen that replaces 5-FU/LV with potentially more active systemic therapy (ECF) improves overall (OS). Methods: Patients resected adenocarcinoma were randomly assigned either: Arm A: 1 cycle 425 mg/m2/day plus LV20 5...
11 Background: In the phase 2 CheckMate 142 trial, nivolumab plus low-dose ipilimumab provided robust and durable clinical benefit was well tolerated as first-line therapy for microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) (Lenz et al. Ann Oncol 2018;29:LBA18). Longer follow-up data will be presented. Methods: Patients with MSI-H/dMMR mCRC no prior treatment disease received 3 mg/kg every weeks 1 6 until progression or...
Abstract Purpose: Thioredoxin-1 (Trx-1) is a cellular redox protein that promotes tumor growth, inhibits apoptosis, and up-regulates hypoxia-inducible factor-1α vascular endothelial growth factor. Objectives of this study were to determine safety, tolerability, pharmacodynamics, pharmacokinetics PX-12, small-molecule inhibitor Trx-1. Experimental Design: Thirty-eight patients with advanced solid tumors received PX-12 at doses 9 300 mg/m2, as 1- or 3-h i.v. infusion on days 1 5, repeated...
4040 Background: In the phase 2 CheckMate 142 trial, NIVO + low-dose IPI had robust, durable clinical benefit and was well tolerated as 1L therapy for MSI-H/dMMR mCRC (median follow-up 13.8 months [mo; range, 9–19]; Lenz et al. Ann Oncol 2018;29:LBA18). Longer is presented here. Methods: Patients (pts) with no prior treatment metastatic disease received 3 mg/kg Q2W 1 Q6W until progression or discontinuation. The primary endpoint investigator-assessed (INV) objective response rate (ORR) per...
Background: In this international multicenter study, we aimed to determine the independent risk factors associated with increased 30 day mortality and impact of cancer novel treatment modalities in a large group patients without COVID-19 from multiple countries. Methods: We retrospectively collected de-identified data on cohort diagnosed between January November 2020 16 centers. Results: analyzed 3966 confirmed patients, 1115 2851 patients. Patients were more likely be pancytopenic have...
Objectives: Cycloxygenase-2 (COX-2) is overexpressed in pancreatic tumors where it may be involved inflammation, carcinogenesis, and the regulation of neoangiogenesis. The purpose this trial was to evaluate combination intravenous gemcitabine with selective COX-2 inhibitor, celecoxib for effect on survival, disease progression, tolerability patients advanced cancer. In addition, limited pharmacokinetic pharmacodynamic analyses were preformed. Materials Methods: Eligible included those...
Abstract Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with checkpoint inhibitor nivolumab patients locally advanced or metastatic solid tumors. Patients Methods: This a multicenter, dose-finding (phase I), dose expansion II) (NCT02705105) There were no dose-limiting toxicities phase I mogamulizumab 1 mg/kg every week for cycle...
97 Background: NIVO + IPI demonstrated robust, durable clinical benefit and was well tolerated as a 1L therapy in pts with MSI-H/dMMR mCRC the phase 2 CheckMate 142 study (NCT02060188), leading to inclusion of NCCN guidelines an initial option for these pts. At 52-mo median follow-up, continued demonstrate benefit, no new safety signals were identified. Here we report longer follow-up results. Methods: Pts prior treatment metastatic disease received 3 mg/kg Q2W 1 Q6W until progression or...
Purpose Imexon, a pro-oxidant small molecule, has antitumor activity in preclinical models. The drug induces apoptosis through accumulation of reactive oxygen species. purpose this trial was to define the maximum-tolerated dose (MTD), toxicities, pharmacokinetics, and pharmacodynamics imexon patients with advanced cancers. Patients Methods Forty-nine metastatic cancer received intravenous over 30 45 minutes for 5 consecutive days (one course) every other week (days 1 15 19) monthly. Doses...